Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

Objective Despite a multitude of detection and treatment advances in the past 2 decades,
prostate cancer remains the second leading cause of deaths due to cancer among men in …

Purpose: We have synthesized and evaluated in vivo 2-(3-{1-carboxy-5-[(6-[18F] fluoro-
pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid,[18F] DCFPyL, as a potential …

Glutamate carboxypeptidase II (GCPII) is a membrane-bound binuclear zinc
metallopeptidase with the highest expression levels found in the nervous and prostatic …

Prostate cancer (PCa) is the second leading cause of cancer-related death in American
men. Positron emission tomography/computed tomography (PET/CT) with emerging …

Identification of cancer cell–surface biomarkers and advances in antibody engineering have
led to a sharp increase in the development of therapeutic antibodies. These same advances …

Immuno-positron emission tomography (immunoPET) is a molecular imaging modality
combining the high sensitivity of PET with the specific targeting ability of monoclonal …

Prostate-specific membrane antigen (PSMA) is a well-recognized target for identification and
therapy of a variety of cancers. Here we report five 64Cu-labeled inhibitors of PSMA,[64Cu] …

Prostate cancer (CaP) is the most common noncutaneous malignancy affecting men in North
America. Despite significant efforts, conventional imaging of CaP does not contribute to …

Simple Summary One of the most frequently diagnosed cancer in men is adenocarcinoma of
the prostate. Once the disease is metastatic, only very limited treatment options are …